Company intelligence / Profile preview

Triphase Accelerator

Toronto, Ontario, Canadatriphaseco.com ↗

Ownership: Private
Development stage: Other

Overview

TRPH‑222 showed positive updated Phase 1 data in relapsed/refractory B-cell non-Hodgkin’s lymphoma with an overall response rate of ~54%, complete response rate of ~38%, median duration of response ~25 months, and favorable safety profile. Marizomib was advanced to Phase 3 by Celgene after acquisition.

Therapeutic areas: OncologyHematology
Modalities: Antibody-drug conjugates (ADCs)Small moleculesMonoclonal antibodies
Industry: Biotech

Drug pipeline

3 assets

trph-222

2 more assets in the full pipeline.

Partnerships

Celgene Corporation/Bristol Myers Squibb – multiple oncology collaborations including option/acquisition deals for pipeline assets such as marizomib and TRPH‑395Catalent Biologics for ADC technology licensingOntario Institute for Cancer Research, MaRS Innovation/FACIT/TIAP as founding partners/funders.

Beyond the preview

Go deeper on Triphase Accelerator.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Triphase Accelerator.